About Glee Biotech
Glee Biotech is a Healthcare company based in Delhi (India) founded in 2020. It develops and manufactures a range of pharmaceutical products, including generic and branded medications. It operates on a B2B model. Its Indian entity Glee Biotech Limited reported revenue of ₹17.11 Cr. Its focus areas include Pharmaceuticals, Manufacturing and Drug Production. Its competitors include Unither, Akums, Jubilant Life Sciences, Recipharm and CoreRx and 3 more; 4 of its 8 listed competitors have raised funding.
Company details
Glee Biotech develops and manufactures a range of pharmaceutical products, including generic and branded medications through providing healthcare solutions, producing pharmaceutical products, producing manufactured goods, and drug production. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field.
- Headquarters Delhi, India
- SectorsHealthcare
- Website gleebiotech.com
- Legal Name Glee Biotech Limited
- Date of Incorporation 03 Mar, 2020
- Jurisdiction New Delhi, Delhi, India
- Annual Revenue₹17.11 Cr
FY 2024 · -7% YoY
- Net Profit₹2.92 Cr
FY 2024 · 17% margin
- EBITDA₹3.91 Cr
FY 2024 · 23% margin
Associated legal entities of Glee Biotech
Glee Biotech operates through Glee Biotech Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Glee Biotech Limited CIN U33100DL2020PLC362536 | Active | 03 Mar 2020 | New Delhi, Delhi | ₹17.1 Cr | 8 | 3 | View details |
Board of directors of Glee Biotech Limited (Glee Biotech)
Glee Biotech Limited is the primary company behind Glee Biotech. The board of Glee Biotech Limited currently have 3 directors; the longest-serving is Rachna Bhatia, appointed in 2020. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rachna Bhatia DIN 08715610 | Director | 03 Mar 2020 | 6 yrs 7 mo | Glee Biotech Limited |
| Raghav Bhatia DIN 08715611 | Director | 03 Mar 2020 | 6 yrs 7 mo | Glee Biotech Limited |
| Kiran Bhatia DIN 08987674 | Director | 08 Dec 2020 | 5 yrs 10 mo | Glee Biotech Limited |
Financials of Glee Biotech
Figures of Glee Biotech Limited, the primary company behind Glee Biotech, for FY 2024. Revenue was ₹17.11 Cr (-7% year on year). Net profit was ₹2.92 Cr (17% margin). EBITDA was ₹3.91 Cr (23% margin). Revenue has grown at a compounded annual rate of +26% over three years.
- ₹17.11 CrRevenue · FY 2024 · -7% YoY
- ₹2.92 CrNet profit · 17% margin
- ₹3.91 CrEBITDA · 23% margin
- ₹5 LakhPaid-up capital
- 8Employees (provident fund records)
- +26%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Glee Biotech Limited are on its company page.
Detailed financial statements for Glee Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Glee Biotech
Glee Biotech has 8 listed competitors in our database, 4 of them funded. They include Unither, Akums, Jubilant Life Sciences, Recipharm and CoreRx, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| unither-pharma.com | 1993 | Paris, France | – | – | Contract development and manufacturing organization for proprietary and generic drugs | |
| akums.in | 2004 | Delhi, India | $70M | 395 | CDMO focusing on spectrum of dosage forms and therapeutic segments | |
| jubl.com | 1978 | Noida, India | – | – | Company offering a suite of R&D and manufacturing services for small molecules and generics | |
| recipharm.com | 1995 | Jordbro, Sweden | – | 1,083 | Pharmaceutical development and manufacturing services are offered contractually. | |
| corerxpharma.com | 2006 | Clearwater, United States | $15M | – | CDMO with a focus on early phase drug product development | |
| neclife.com | 1995 | Chandigarh, India | $46.85M | 175 | Cephalosporin APIs and generic formulations are manufactured. | |
| windlas.com | 2001 | Gurugram, India | $12.96M | 1,264 | Biopharma regulatory affairs, quality control, and strategy services are provided. | |
| medpharm.com | 1998 | Guildford, United Kingdom | – | 108 | Topical and inhaled drug delivery formulations are developed and manufactured. |
Detailed competitors of Glee Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Glee Biotech (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Glee Biotech
Glee Biotech was founded in 2020.
Glee Biotech is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.
The primary company behind Glee Biotech, Glee Biotech Limited, reported revenue of ₹17.11 Cr for FY 2024, down 7% year on year.
Glee Biotech develops and manufactures a range of pharmaceutical products, including generic and branded medications through providing healthcare solutions, producing pharmaceutical products, producing manufactured goods, and drug production. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field.
Glee Biotech's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
Glee Biotech operates through Glee Biotech Limited.
The legal entities of Glee Biotech currently have 3 directors, including Rachna Bhatia, Raghav Bhatia, Kiran Bhatia.